ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN ERITROPOETIN (HEMAPO® , EPOTREX®, NEORECORMON®) PADA PASIEN HEMODIALISIS DI RSUP PERSAHABATAN

Chandra Widianti, Yusi Anggriani, Tri Kusumaeni, Okpri Meila

Abstract


Abstrak. Penerapan INA-CBGs (Indonesia Case Base Groups) di era JKN mendorong penyedia layanan kesehatan, untuk menghitung biaya yang dikeluarkan agar tidak merugi. Pada pasien Gagal Ginjal Kronis (GGK) yang menjalani hemodialisis, prevalensi anemia cukup tinggi, sehingga diberikan eritropoetin (EPO). Dibutuhkan penelitian untuk mengetahui dari beberapa jenis EPO, mana yang lebih cost-effective. Penelitian deskriptif non-eksperimental dilakukan di Unit Hemodialisa Rumah Sakit Persahabatan. Efektivitas terapi ditentukan oleh peningkatan kadar hemoglobin (Hb) setelah 3 (tiga) bulan berturut-turut mendapatkan terapi EPO yang sama. Analisis efektivitas-biaya diperoleh dengan menghitung nilai CER (Cost-Effectiveness Ratio). Hasil menunjukkan penggunaan Neorecormon® memiliki efektivitas yang lebih tinggi dengan persentase jumlah pasien yang mengalami peningkatan Hb sebesar 56,41% dibandingkan Hemapo® (54%) dan Epotrex® (52,63%). Total biaya pengobatan rata-rata dengan Hemapo® , Epotrex® dan Neorecormon® masing-masing Rp. 32.552.117, Rp. 34.787.487 dan Rp. 32.866.969. Hasil perhitungan nilai CER dalam penggunaan Neorecormon® untuk pasien yang mengalami peningkatan Hb adalah Rp 58.264.437, lebih kecil daripada Hemapo® (Rp. 60.281.698) and Epotrex® (Rp. 66.098.208). Berdasarkan nilai CER dan tabel efektivitas-biaya, menunjukkan bahwa Neorecormon® adalah pilihan terapi yang lebih cost-effective daripada Hemapo® dan Epotrex®.

Kata-kata kunci: Analisis efektivitas-biaya, hemodialisis, eritropoetin

Abstract. INA-CBGs (Indonesia Case Base Groups) in JKN era, encourages health care providers to calculate costs incurred so as not to lose money. In Chronic Renal Failure (CRF) patients who undergo hemodialysis, anemia prevalence is high enough to require administration of erythropoietin (EPO). Its necessary to investigate the therapeutic treatment from several types of EPO, which is more cost-effective. Descriptive non-experimental research conducted in the Hemodialysis Unit in Persahabatan Hospital. The effectiveness determined by an increased in hemoglobin (Hb) levels after three (3) months earned the same EPO therapy. Cost-effectiveness analysis is obtained by calculated the CER (Cost-Effectiveness Ratio). The results shows that Neorecormon® have a higher effectiveness with the percentage of patients whose Hb level increase by 56.41% comparing to Hemapo® (54%) and Neorecormon® (52.63%). The average total cost with Hemapo®, Epotrex® and Neorecormon® each successive Rp. 32.552.117, Rp. 34.787.487 and Rp. 32.866.969. The CER value of Neorecormon® show cost-effectiveness of Rp 58.264.437 for a patient with an increase in Hb, smaller than Hemapo® (Rp. 60.281.698) and Epotrex® (Rp. 66.098.208). Based on CER value and cost effectiveness grid, shows that Neorecormon® is the choice that is more cost-effective than Hemapo® and Epotrex®.

 Keywords : Cost effectiveness analysis, hemodialysis, erythropoetin


Keywords


Analisis efektivitas-biaya, hemodialisis, eritropoetin ; Analisis efektivitas-biaya, hemodialisis, eritropoetin

Full Text:

PDF

References


Daftar Pustaka

Wells, BG, Dipiro, JT, Schwinhammer, TL, Dipiro, CV. Pharmacotherapy Principles & Practice. New York : McGraw Hill Medical; 2009

Indonesian Renal Registry. 5th Report Of Indonesian Renal Registry; 2012

Black, JM, Hawks, JH Medical. Surgical Nursing : Clinical management for Positive Outcomes. 8th ed. Elsevier. Inc; 2009

Smeltzer & Bare. Textbook of Medical Surgical Nursing Vol. 2. Philadelphia : Linppincott William & Wilkins; 2008

Lewis, SL, et al. Medical, Surgical, Nursing : Assessment and Management of Clinical Problems. 8th ed. Elsevier. Inc; 2011

National Kidney & Urologic Disease Information Clearinghouse (NKUDIC). Treatment methods for kidney failure : Hemodialysis. 2006; Available from : URL: http://kidney.niddk.nih.gov/KUDiseases/ pubs/hemodialysis/.

PERNEFRI. Manajemen Anemia pada Pasien Gagal Ginjal Kronik. Jakarta; 2011

National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease 2000. Am J Kidney DS 37 (suppl 1) 2001; p : 180-238

Treatment of Renal Anemia. Nephrol Dial Transplant ; 19 (suppl 2) 2004; p : ii16-ii31

BMJ Group. British National Formulary (BNF) 61. London : BMJ Group and the Royal Pharmaceutical Society of Great Britain 2011; p. 494-502

Sudoyo, AW, et al. (Ed). Buku Ajar : Ilmu Penyakit Dalam (4th ed). Jilid III. Jakarta : Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia; 2007

Rully MA Roesli, Enday Sukandar, Rubin Gondodiputro, Rachmat Permana : Kenaikan Kadar Hemoglobin setelah Pemberian Epoetin Apha (HEMAPO®) selama 12 minggu, pada Penderita Gagal Ginjal yang menjalani Hemodialisis. Cermin Dunia Kedokteran no. 147 2005

Tilkian EE, Tzekov VD, Pandeva SM, Kumchev EP, Nikolov DG, Dimitrakov JD, Epoetin-beta (Recormon-Roche) in The Treatment of Renal Anemia in Patients with Chronic Renal Failure; 2000

Trisna, Y. Aplikasi Farmakoekonomi, Ikatan Apoteker Indonesia; 2008. Available from :URL: http://www.ikatanapotekerindonesia.net/articles/pharmaupdate/national-pharmacy/311-aplikasi-farmakoekonomi.html.

Primadinta, Triyani Marwati, Solikhah. Analisis Cost Sharing Perhitungan Tarif Hemodialisis (HD) Masyarakat Miskin di Rumah Sakit Umum PKU Muhammadiyah Unit I Yogyakarta. KesMas Vol. 5 No.3 2011; p : 162-232

Indonesian Renal Registry. 7th Report Of Indonesian Renal Registry; 2014

Ulya, I, Suryanto. Perbedaan kadar Hb pra dan post Hemodialisa pada Penderita Gagal Ginjal Kronis di RS PKU Muhamadiyah Yogyakarta. Mutiara Medika Vol 7 (1); 2007.

Henry Ford Health System. Chronic Kidney Disease, Clinical Practice Recomendations For Primary Care Physicians and Healthcare Providers. Divisions of Nephrology & Hypertension and General Internal Medicine ; 2011

National Kidney Foundation, KDOQI. Clinical Practice Guideline for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis 39:SI-S266; 2002

Cahyono, JB, Suharjo. Gaya Hidup dan Penyakit Modern. Yogyakarta: Departemen Kesehatan Republik Indonesia; 2009

Muharni, Sri Idia. Pola Hidup Penderita Gagal Ginjal Kronik Sebelum Menjalani Terapi Hemodialisis di RSUD Kota Langsa Tahun 2009. Medan; 2009

Loughnan, A, Ali, CR, Abeygunasekara, SC. Comparison of Therapeutic Efficacy of Epoetin Beta and Epoetin Apha in Maintenance Phase Hemodialysis Patients; 2011.

Fransesco Locatelly, et al. Dialysis Adequacy And Response to Erythropoeisis Stimulating Agents : What is The Evidence Base ?. Departement Of Nephrology and Dialysis Lecco Italy: Elsevier Inc; 2006

Lukito, Benyamin. Anemia pada Gagal Ginjal Kronik. Medicinus; 2008

Deray, G. Achieving Therapetic Targets in Renal Anemia: Considering Cost Efficacy. Medline 2004; 20:7 (1095-1101)




DOI: https://doi.org/10.24815/jks.v18i3.18017

Refbacks

  • There are currently no refbacks.



Creative Commons LicenseISSN: 1411-3848E-ISSN: 2579-6372
Copyright© 1987-2017 | ISSN: 1412-1026 | EISSN: 2550-0112 
Jurnal Kedokteran Syiah Kuala is licensed under a Creative Commons Attribution 4.0 International License.

 

Published by:
Fakultas Kedokteran, Universitas Syiah Kuala
 
Jl. Tgk. Tanoh Abee, Kopelma Darussalam,
Banda Aceh, 23111, Indonesia.
Phone: +626517551843 
Email: jks@unsyiah.ac.id


Online Submissions & Guidelines | Editorial Policies | Contact | Statistics | Indexing | Citations